Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Ocadusertib?
Ocadusertib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Rheumatoid Arthritis....
Data Insights
Ocadusertib by Eli Lilly and Co for Rheumatoid Arthritis: Likelihood of Approval
Ocadusertib is under clinical development by Eli Lilly and Co and currently in Phase II for Rheumatoid Arthritis. According to...